NCT06691529Not yet recruiting
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
The Association of Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
Source: ClinicalTrials.gov · Last updated 18 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The association of metabolic associated fatty liver disease in patients with chronic glomerular disease
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 14 Nov 2024
- Start date
- Dec 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- Assiut University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06691529
What you commit to
- Study type: Observational
- Planned participants: 500
- From Dec 2024 to the primary completion date, Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with previous/current HBV or HCV.
- Patient commencing any hepatotoxic medication.
Other
- CKD patients of Unknown etiology.
- CKD patients with liver cirrhosis.
- CKD patients secondry to documented diabetic nephropathy.
- Pregnant CKD patients.
Who the study is looking for
- All CKD patient aging between (18-70) years with known tubule-glomerular diseases.
- At any eGFR.
- All CKD patient have either type I/II DM associated with CKD .
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.